Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry

Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice

(2014) Aline Frazier-Mironer et al.   JOINT BONE SPINE

Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate

(2014) Tomonori Kobayakawa et al.   Modern Rheumatology

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab

(2013) M Neovius et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

(2013) Irini Flouri et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

(2012) Jeffrey D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

(2012) Charlotte L. Krieckaert et al.   ARTHRITIS AND RHEUMATISM

Longterm Retention of Tumor Necrosis Factor-  Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

(2012) F. IANNONE et al.   JOURNAL OF RHEUMATOLOGY

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

(2011) M. M. Soliman et al.   ANNALS OF THE RHEUMATIC DISEASES

Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

(2011) J. A. MARKENSON et al.   JOURNAL OF RHEUMATOLOGY

Survivor treatment bias, treatment selection bias, and propensity scores in observational research

(2010) Peter C. Austin et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register

(2010) W. Kievit et al.   RHEUMATOLOGY

TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice

(2009) Antonio Marchesoni et al.   Annals of the New York Academy of Sciences

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

(2009) G. M. Bartelds et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

(2009) Sophie Martin Du Pan et al.   ARTHRITIS AND RHEUMATISM

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM

Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid Arthritis

(2009) Y. YAZICI et al.   JOURNAL OF RHEUMATOLOGY

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal

(2008) Roberto Caporali et al.   AUTOIMMUNITY REVIEWS

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET